Pub Date : 2024-05-01DOI: 10.1097/ipc.0000000000001365
Elizabeth Costanzo, Kaylee Maynard, Ted Louie, Stephanie Shulder, John Gorczyca, Courtney MC Jones, Michael Croix, R. Alpizar-Rivas, Patricia Escaler, Jason Lipof, Nicole M. Acquisto
The Eastern Association for the Surgery of Trauma guidelines provide antibiotic selection recommendations based on open fracture type. However, risk factors for open fracture complications (eg, infection, acute kidney injury [AKI], multi-drug resistant organisms, or Clostridioides infection [C. difficile]) and overall antibiotic prophylaxis guideline adherence are unclear at our institution. This is a retrospective, observational study of patients who received antibiotic prophylaxis between March 2011 and October 2020 at a level 1 trauma center. We sought to identify open fracture injury complications and assess adherence to institution antibiotic prophylaxis guidelines. Descriptive data and bivariate analyses are reported. Multivariable logistic regression was performed to identify independent risk factors associated with infectious complications. A total of 401 patients met study criteria; median age of 48 ± 20 years, 62% male. Fracture classifications were similar: 30% type I, 39% type II, and 30% type III. Infection occurred in 18.5% of patients, AKI in 20.3%, multi-drug resistant organism in 3%, and no patients developed C. difficile. Eighty-one percent received guideline adherent antibiotics. In bivariate analysis, fracture classification (P = 0.02) and antibiotic choice (P = 0.004) were associated with infection. Receiving a concomitant nephrotoxic medication was associated with AKI (P = 0.01). In logistic regression, only fracture classification was reliably and independently associated with occurrence of infection. Appropriate fracture classification and antibiotic choice is important to reduce infection following open fracture. Reducing concomitant exposure to nephrotoxic agents may reduce the risk of AKI.
{"title":"Risk Factors Associated With Open Fracture Complications Following Antibiotic Prophylaxis","authors":"Elizabeth Costanzo, Kaylee Maynard, Ted Louie, Stephanie Shulder, John Gorczyca, Courtney MC Jones, Michael Croix, R. Alpizar-Rivas, Patricia Escaler, Jason Lipof, Nicole M. Acquisto","doi":"10.1097/ipc.0000000000001365","DOIUrl":"https://doi.org/10.1097/ipc.0000000000001365","url":null,"abstract":"\u0000 \u0000 The Eastern Association for the Surgery of Trauma guidelines provide antibiotic selection recommendations based on open fracture type. However, risk factors for open fracture complications (eg, infection, acute kidney injury [AKI], multi-drug resistant organisms, or Clostridioides infection [C. difficile]) and overall antibiotic prophylaxis guideline adherence are unclear at our institution.\u0000 \u0000 \u0000 \u0000 This is a retrospective, observational study of patients who received antibiotic prophylaxis between March 2011 and October 2020 at a level 1 trauma center. We sought to identify open fracture injury complications and assess adherence to institution antibiotic prophylaxis guidelines. Descriptive data and bivariate analyses are reported. Multivariable logistic regression was performed to identify independent risk factors associated with infectious complications.\u0000 \u0000 \u0000 \u0000 A total of 401 patients met study criteria; median age of 48 ± 20 years, 62% male. Fracture classifications were similar: 30% type I, 39% type II, and 30% type III. Infection occurred in 18.5% of patients, AKI in 20.3%, multi-drug resistant organism in 3%, and no patients developed C. difficile. Eighty-one percent received guideline adherent antibiotics. In bivariate analysis, fracture classification (P = 0.02) and antibiotic choice (P = 0.004) were associated with infection. Receiving a concomitant nephrotoxic medication was associated with AKI (P = 0.01). In logistic regression, only fracture classification was reliably and independently associated with occurrence of infection.\u0000 \u0000 \u0000 \u0000 Appropriate fracture classification and antibiotic choice is important to reduce infection following open fracture. Reducing concomitant exposure to nephrotoxic agents may reduce the risk of AKI.\u0000","PeriodicalId":13952,"journal":{"name":"Infectious Diseases in Clinical Practice","volume":null,"pages":null},"PeriodicalIF":0.5,"publicationDate":"2024-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141052801","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-05-01DOI: 10.1097/ipc.0000000000001378
Kenneth S. Rosenthal
{"title":"Comments on “Lessons From the Global SARS-CoV-2 Health Emergency for Potential Future Pandemics”","authors":"Kenneth S. Rosenthal","doi":"10.1097/ipc.0000000000001378","DOIUrl":"https://doi.org/10.1097/ipc.0000000000001378","url":null,"abstract":"","PeriodicalId":13952,"journal":{"name":"Infectious Diseases in Clinical Practice","volume":null,"pages":null},"PeriodicalIF":0.5,"publicationDate":"2024-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141050799","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-03-01DOI: 10.1097/ipc.0000000000001359
Diogo Goulart Corrêa, Celso Dias Coelho Filho, Marcello Baptista Soares Maravilha, Aquiles Jose Vasconcellos Mamfrim, L. C. Hygino da Cruz
{"title":"Acute Optic Nerve Ischemia in a Diabetic Patient","authors":"Diogo Goulart Corrêa, Celso Dias Coelho Filho, Marcello Baptista Soares Maravilha, Aquiles Jose Vasconcellos Mamfrim, L. C. Hygino da Cruz","doi":"10.1097/ipc.0000000000001359","DOIUrl":"https://doi.org/10.1097/ipc.0000000000001359","url":null,"abstract":"","PeriodicalId":13952,"journal":{"name":"Infectious Diseases in Clinical Practice","volume":null,"pages":null},"PeriodicalIF":0.5,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140090723","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-02-19DOI: 10.1097/ipc.0000000000001349
Christopher Bollinger, Zachary Carroll, Valeria Laboy Collazo, Brian Murray
Pseudomonas aeruginosa (PA) is commonly implicated in ventilator-associated pneumonia (VAP). Consensus guidelines for VAP recommend a 7-day course of appropriate antibiotics. However, recent studies have shown higher recurrence rates of PA pneumonia with shorter courses of antibiotics. This study was designed to compare PA pneumonia recurrence rates in patients who received appropriate antibiotics for ≤7 days vs >7 days. A retrospective, single-center, observational cohort study of adults diagnosed with PA-VAP between January 2017 and May 2022 was conducted. Patients were divided into a >7-day cohort or a ≤7-day cohort based on duration of appropriate antibiotics. The primary outcome was the recurrence rate of PA pneumonia. A total of 106 patients were included, 59 in the >7-day cohort and 47 in the ≤7-day cohort. The median (interquartile range) duration of appropriate antipseudomonal therapy was 12 days (8–18 days) in the >7-day cohort and 7 days (6–7 days) in the ≤7-day cohort. Pseudomonas aeruginosa recurrence was observed in 15 (25.4%) patients in the >7-day cohort and 20 (42.6%) patients in the ≤7-day cohort (P = 0.059). Over 33% of patients in the >7-day cohort had persistently positive PA cultures after at least 7 days of appropriate antibiotic therapy. Extending duration of antipseudomonal antibiotics beyond 7 days did not significantly reduce the recurrence of PA pneumonia. However, the lower rate of recurrence in the >7-day group and high rate of persistent positive cultures may be clinically significant, suggesting a role for extended treatment. Further prospective studies are needed to determine the optimal duration of therapy for PA-VAP.
{"title":"Evaluation of Recurrence Rates of Pseudomonas Pneumonia in Mechanically Ventilated ICU Patients Receiving ≤7 Versus >7 Days of Antibiotic Therapy","authors":"Christopher Bollinger, Zachary Carroll, Valeria Laboy Collazo, Brian Murray","doi":"10.1097/ipc.0000000000001349","DOIUrl":"https://doi.org/10.1097/ipc.0000000000001349","url":null,"abstract":"\u0000 \u0000 \u0000 Pseudomonas aeruginosa (PA) is commonly implicated in ventilator-associated pneumonia (VAP). Consensus guidelines for VAP recommend a 7-day course of appropriate antibiotics. However, recent studies have shown higher recurrence rates of PA pneumonia with shorter courses of antibiotics. This study was designed to compare PA pneumonia recurrence rates in patients who received appropriate antibiotics for ≤7 days vs >7 days.\u0000 \u0000 \u0000 \u0000 A retrospective, single-center, observational cohort study of adults diagnosed with PA-VAP between January 2017 and May 2022 was conducted. Patients were divided into a >7-day cohort or a ≤7-day cohort based on duration of appropriate antibiotics. The primary outcome was the recurrence rate of PA pneumonia.\u0000 \u0000 \u0000 \u0000 A total of 106 patients were included, 59 in the >7-day cohort and 47 in the ≤7-day cohort. The median (interquartile range) duration of appropriate antipseudomonal therapy was 12 days (8–18 days) in the >7-day cohort and 7 days (6–7 days) in the ≤7-day cohort. Pseudomonas aeruginosa recurrence was observed in 15 (25.4%) patients in the >7-day cohort and 20 (42.6%) patients in the ≤7-day cohort (P = 0.059). Over 33% of patients in the >7-day cohort had persistently positive PA cultures after at least 7 days of appropriate antibiotic therapy.\u0000 \u0000 \u0000 \u0000 Extending duration of antipseudomonal antibiotics beyond 7 days did not significantly reduce the recurrence of PA pneumonia. However, the lower rate of recurrence in the >7-day group and high rate of persistent positive cultures may be clinically significant, suggesting a role for extended treatment. Further prospective studies are needed to determine the optimal duration of therapy for PA-VAP.\u0000","PeriodicalId":13952,"journal":{"name":"Infectious Diseases in Clinical Practice","volume":null,"pages":null},"PeriodicalIF":0.5,"publicationDate":"2024-02-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140449633","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-01-15DOI: 10.1097/ipc.0000000000001344
Ishwari Pandey, Sumita Pai, Rushmi D Purmessur, Ruth Kappeler, Jason M. Ali
Kytococcus schroeteri is a gram-positive coccus naturally found as part of the normal skin flora. Infection caused by this organism is not common but seems to be limited to patients with implanted prostheses. To date, there have been only 22 reported cases of K. schroeteri causing disease, of which 9 are cases of prosthetic valve endocarditis. In this review, we report on 3 further cases of K. schroeteri prosthetic valve endocarditis and review the previously reported cases. The common theme is one of delayed diagnosis, with the organism not initially identified, often after initially being misdiagnosed as a Micrococcus species. Prosthetic valve endocarditis caused by K. schroeteri is commonly associated with large vegetations leading to patients often requiring surgical intervention after embolic events or to prevent them. There is currently no guidance in relation to the antimicrobial treatment, but a combination of vancomycin with rifampicin and gentamicin for 6 weeks has been noted to be efficacious.
{"title":"Kytococcus schroeteri","authors":"Ishwari Pandey, Sumita Pai, Rushmi D Purmessur, Ruth Kappeler, Jason M. Ali","doi":"10.1097/ipc.0000000000001344","DOIUrl":"https://doi.org/10.1097/ipc.0000000000001344","url":null,"abstract":"\u0000 \u0000 Kytococcus schroeteri is a gram-positive coccus naturally found as part of the normal skin flora. Infection caused by this organism is not common but seems to be limited to patients with implanted prostheses. To date, there have been only 22 reported cases of K. schroeteri causing disease, of which 9 are cases of prosthetic valve endocarditis. In this review, we report on 3 further cases of K. schroeteri prosthetic valve endocarditis and review the previously reported cases. The common theme is one of delayed diagnosis, with the organism not initially identified, often after initially being misdiagnosed as a Micrococcus species. Prosthetic valve endocarditis caused by K. schroeteri is commonly associated with large vegetations leading to patients often requiring surgical intervention after embolic events or to prevent them. There is currently no guidance in relation to the antimicrobial treatment, but a combination of vancomycin with rifampicin and gentamicin for 6 weeks has been noted to be efficacious.","PeriodicalId":13952,"journal":{"name":"Infectious Diseases in Clinical Practice","volume":null,"pages":null},"PeriodicalIF":0.5,"publicationDate":"2024-01-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139622893","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-01-15DOI: 10.1097/ipc.0000000000001339
Yasemin Oz, Ebru Karakoç, Serap Kara, N. Kasifoglu, T. Us, Birgul Yelken, M. Bilgin, G. Durmaz
Bacterial secondary infections were commonly reported in viral respiratory tract infections. However, it is not clear whether there is a difference in the infection rates during the hospitalization in intensive care unit (ICU) caused by COVID-19. The aim of this study was to evaluate the secondary infections in long-term hospitalized patients in the ICU due to COVID-19 and whether COVID-19 increases the tendency to secondary infection in ICU patients. This is a retrospective case-control study. It was conducted in a tertiary care hospital including 34-bed COVID-19 ICU and 20-bed non–COVID-19 ICU. Adult patients in the ICU hospitalized for ≥10 days were included the study. The results of microbiological cultures of blood, urine, and respiratory samples were evaluated in terms of infections during their hospitalization. The study group consisted of 51 patients with COVID-19 and the control group consisted of 57 non–COVID-19 patients. There was no significant difference between 2 groups in terms of distribution and frequency of agents isolated from blood culture. The frequency of isolation of Enterobacterales members in urine cultures and nonfermenting bacteria in respiratory samples were significantly higher in non–COVID-19 patients compared with COVID-19 patients (P < 0.05). This study revealed that there was no difference among the patients with and without COVID-19 in ICU for the secondary infections when the ICU stay was prolonged. We think that prolonged hospitalization, urinary catheterization, and mechanical ventilation are more important risk factors for secondary infections in ICUs and COVID-19 does not occur an additional risk factor in prolonged ICU stay.
{"title":"Comparison of COVID-19 and Non–COVID-19 Patients in Intensive Care Unit for Secondary Infections","authors":"Yasemin Oz, Ebru Karakoç, Serap Kara, N. Kasifoglu, T. Us, Birgul Yelken, M. Bilgin, G. Durmaz","doi":"10.1097/ipc.0000000000001339","DOIUrl":"https://doi.org/10.1097/ipc.0000000000001339","url":null,"abstract":"\u0000 \u0000 Bacterial secondary infections were commonly reported in viral respiratory tract infections. However, it is not clear whether there is a difference in the infection rates during the hospitalization in intensive care unit (ICU) caused by COVID-19. The aim of this study was to evaluate the secondary infections in long-term hospitalized patients in the ICU due to COVID-19 and whether COVID-19 increases the tendency to secondary infection in ICU patients.\u0000 \u0000 \u0000 \u0000 This is a retrospective case-control study. It was conducted in a tertiary care hospital including 34-bed COVID-19 ICU and 20-bed non–COVID-19 ICU. Adult patients in the ICU hospitalized for ≥10 days were included the study. The results of microbiological cultures of blood, urine, and respiratory samples were evaluated in terms of infections during their hospitalization.\u0000 \u0000 \u0000 \u0000 The study group consisted of 51 patients with COVID-19 and the control group consisted of 57 non–COVID-19 patients. There was no significant difference between 2 groups in terms of distribution and frequency of agents isolated from blood culture. The frequency of isolation of Enterobacterales members in urine cultures and nonfermenting bacteria in respiratory samples were significantly higher in non–COVID-19 patients compared with COVID-19 patients (P < 0.05).\u0000 \u0000 \u0000 \u0000 This study revealed that there was no difference among the patients with and without COVID-19 in ICU for the secondary infections when the ICU stay was prolonged. We think that prolonged hospitalization, urinary catheterization, and mechanical ventilation are more important risk factors for secondary infections in ICUs and COVID-19 does not occur an additional risk factor in prolonged ICU stay.\u0000","PeriodicalId":13952,"journal":{"name":"Infectious Diseases in Clinical Practice","volume":null,"pages":null},"PeriodicalIF":0.5,"publicationDate":"2024-01-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139622080","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-01-15DOI: 10.1097/ipc.0000000000001335
Mathew John, Sunny P. Orathel, Jaicob Varghese, Manu Pradeep, Q. M. Jacob, Ronnie Thomas, Salini Baby John, Venkataraghavan Ramamoorthy, A. Saxena, M. Rubens
Planning effective preventive and control measures requires understanding of the variability in the severity of infectious illnesses and factors determining susceptibility. The present study aimed to assess the association between familial susceptibility and ABO blood group with COVID-19 disease severity and adverse outcomes. The present study was a retrospective investigation that was carried out at a tertiary care hospital with a bed capacity of 560 in the state of Kerala, India. A structured questionnaire was used to extract demographic and clinical characteristics from screened records. The study participants were stratified into 2 distinct groups based on the severity of their illness: mild to moderate and severe. Familial aggregation was operationally defined as the occurrence of COVID-19 diagnosis in any first-degree relative. A total of 362 hospitalized patients with confirmed COVID-19 infection were included in the analysis. Among them 62 (17.1%) were categorized as severe COVID-19 and 300 (82.9%) were categorized as mild to moderate COVID-19. Binary logistic regression analysis showed that the odds of sever COVID-19 disease was significantly higher among patients with familial aggregation (odds ratio, 2.47; 95% confidence interval, 2.12–2.85) and with non-O blood group (odds ratio, 2.21; 95% confidence interval, 2.01–2.56). The findings of our study highlight the significance of familial aggregation and ABO blood group as crucial factors in determining the severity of COVID-19 disease. Comprehending the interrelationship between these variables and the genetic makeup of the host may hold significance in prognosticating the gravity of COVID-19 consequences.
{"title":"Familial Aggregation and ABO Blood Groups and COVID-19 Severity Among Hospitalized Patients","authors":"Mathew John, Sunny P. Orathel, Jaicob Varghese, Manu Pradeep, Q. M. Jacob, Ronnie Thomas, Salini Baby John, Venkataraghavan Ramamoorthy, A. Saxena, M. Rubens","doi":"10.1097/ipc.0000000000001335","DOIUrl":"https://doi.org/10.1097/ipc.0000000000001335","url":null,"abstract":"\u0000 \u0000 \u0000 Planning effective preventive and control measures requires understanding of the variability in the severity of infectious illnesses and factors determining susceptibility. The present study aimed to assess the association between familial susceptibility and ABO blood group with COVID-19 disease severity and adverse outcomes.\u0000 \u0000 \u0000 \u0000 The present study was a retrospective investigation that was carried out at a tertiary care hospital with a bed capacity of 560 in the state of Kerala, India. A structured questionnaire was used to extract demographic and clinical characteristics from screened records. The study participants were stratified into 2 distinct groups based on the severity of their illness: mild to moderate and severe. Familial aggregation was operationally defined as the occurrence of COVID-19 diagnosis in any first-degree relative.\u0000 \u0000 \u0000 \u0000 A total of 362 hospitalized patients with confirmed COVID-19 infection were included in the analysis. Among them 62 (17.1%) were categorized as severe COVID-19 and 300 (82.9%) were categorized as mild to moderate COVID-19. Binary logistic regression analysis showed that the odds of sever COVID-19 disease was significantly higher among patients with familial aggregation (odds ratio, 2.47; 95% confidence interval, 2.12–2.85) and with non-O blood group (odds ratio, 2.21; 95% confidence interval, 2.01–2.56).\u0000 \u0000 \u0000 \u0000 The findings of our study highlight the significance of familial aggregation and ABO blood group as crucial factors in determining the severity of COVID-19 disease. Comprehending the interrelationship between these variables and the genetic makeup of the host may hold significance in prognosticating the gravity of COVID-19 consequences.\u0000","PeriodicalId":13952,"journal":{"name":"Infectious Diseases in Clinical Practice","volume":null,"pages":null},"PeriodicalIF":0.5,"publicationDate":"2024-01-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139528894","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-01-15DOI: 10.1097/ipc.0000000000001345
Min W. Hwang, Vaughan Washco, Mark Delman
{"title":"A Case Report of an Uncommon Presentation of Purpura Fulminans With Staphylococcus aureus Endocarditis","authors":"Min W. Hwang, Vaughan Washco, Mark Delman","doi":"10.1097/ipc.0000000000001345","DOIUrl":"https://doi.org/10.1097/ipc.0000000000001345","url":null,"abstract":"","PeriodicalId":13952,"journal":{"name":"Infectious Diseases in Clinical Practice","volume":null,"pages":null},"PeriodicalIF":0.5,"publicationDate":"2024-01-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139620818","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-01-15DOI: 10.1097/ipc.0000000000001346
Ali Shah, Joseph P. Myers
Infectious aortitis, often leading to mycotic aortic aneurysm, is an uncommon disease. It is usually caused by either Staphylococcus aureus or Salmonella species. Streptococcus pneumoniae is rarely reported as a cause of aortitis. We report a patient with infectious aortitis in which S. pneumoniae was isolated in blood and tissue cultures from emergent open surgical intervention. A review of the literature suggests that pneumococcal aortitis is an emerging infectious disease with many more cases reported during the last 2 decades than in the previous 50 years. Of the cases reported since 2008, only 9 of 28 patients had an associated source for pneumococcal disease (pneumonia, meningitis, or endocarditis). Physicians should include infectious aortitis in the differential diagnosis of patients with primary pneumococcal bacteremia (no initial defined source).
{"title":"Pneumococcal Aortitis","authors":"Ali Shah, Joseph P. Myers","doi":"10.1097/ipc.0000000000001346","DOIUrl":"https://doi.org/10.1097/ipc.0000000000001346","url":null,"abstract":"\u0000 Infectious aortitis, often leading to mycotic aortic aneurysm, is an uncommon disease. It is usually caused by either Staphylococcus aureus or Salmonella species. Streptococcus pneumoniae is rarely reported as a cause of aortitis. We report a patient with infectious aortitis in which S. pneumoniae was isolated in blood and tissue cultures from emergent open surgical intervention. A review of the literature suggests that pneumococcal aortitis is an emerging infectious disease with many more cases reported during the last 2 decades than in the previous 50 years. Of the cases reported since 2008, only 9 of 28 patients had an associated source for pneumococcal disease (pneumonia, meningitis, or endocarditis). Physicians should include infectious aortitis in the differential diagnosis of patients with primary pneumococcal bacteremia (no initial defined source).","PeriodicalId":13952,"journal":{"name":"Infectious Diseases in Clinical Practice","volume":null,"pages":null},"PeriodicalIF":0.5,"publicationDate":"2024-01-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139621127","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：